Introduction
Postmenopausal osteoporosis (PMO) occurs after 5-7 years of menopause. Estrogen deficiency is the primary reason for the rapid and sustained increase in the rate of bone loss. Estrogen replacement therapy (ERT) is a widely used therapy to treat PMO. Many studies have suggested that estrogen can act directly on bone cells, lymphocytes, and may influence bone metabolism through immunoregulatory and anti-inflammatory activities (1) (2) (3) (4) (5) (6) . In our previous study, we found estrogen enhances the function of CD4 + CD25 + Foxp3 + regulatory T cells (Tregs), which can suppress osteoclast differentiation and bone resorption in vitro (7) . In the present study, estrogen was used as a positive control. Bu-Shen-Ning-Xin Decoction (BSNXD) is composed of traditional Chinese medicinal compounds that are used to treat women with PMO in clinical, and the composition of prescription, the main effective components, function of BSNXD was introduced in Table 1 (8-18 ). We have done many researches on the effects of BSNXD on bone, previously (19, 20) . BSNXD ameliorated the osteoporotic phenotype of ovariectomized mice without affecting the serum estrogen concentration or uterus (21) ; BSNXD modulates mesenchymal stem cell differentiation into osteoblasts (22) ; BSNXD inhibits osteoclastogenesis by abrogating the RANKL-induced NFATc1 and NF-κB signaling pathways through selective estrogen receptors (23) ; BSNXD suppresses osteoclastogenesis via increasing dehydroepiandrosterone to prevent postmenopausal osteoporosis (24) . However, how BSNXD affects immune cells and whether immune cells participate in the effect of BSNXD on bone metabolism is still unclear.
The interaction between immune cells and bone has attracted many attentions, and osteoimmunology is a new discipline that focuses on the influence of immune cells on bone cell function. In the previous work, though we have gotten some development on bone metabolism, but we know little about immune cells on the process of BSNXD treatment. Many immune cells were found can influence bone metabolism, for example, Receptor activator of NF-kB ligand (RANKL), a tumor necrosis factor (TNF) family member that is expressed on activated T cells, is one of the key differentiation and survival factors for osteoclasts and provides a potential link between normal immune responses and bone metabolism (25) . In the present study, we detected the changes of T cells, regulatory T cells, B cells, and even innate immune cells, such as NK cells, γδ T cells, and monocytes to explore whether immune cells participate in the effect of BSNXD on bone metabolism.
Materials and Methods

Media and reagents
Fetal bovine serum (FBS) and phenol red-free minimum essential media (MEM) were purchased from Gibco (Grand Island, NY, USA). Minimum essential media and 17-β-estradiol (E2) were purchased from Sigma-Aldrich 401 Immune regulation, promoting adrenal cortex and sex glands functioning, stimulating bone marrow, enhancing blood coagulation process, improving kidney and heart functioning, diuresis, lowering blood pressure, inhibiting gastric secretions, antitumor, inhibiting epithelial cell proliferation, anti-oxidative and anti-aging (8).
Resistant to microbial action, sympatheticadrenal function, fall blood sugar function, antipyretic, antitumor (9).
Antibacterial, antifungal, suppression of cough, lower blood pressure, trichomonad resistance, antihepatitis, anti-ulcer, immunomodulatory (10).
Immunomodulatory, anti-oxidant, anti-stress, neuro-protective, anti-tumor, liver/eyes/malefertility/glycemia level and hyperlipidemia/blood pressure effects (11) (12) (13) .
Antifungal, central nervous system/cardiovascular system/digestive system effects (14) .
Sexual function/cardiovascular system/ immune function/respiratory system effect, anti-virus (15) .
Sedative and hypnotic, radioprotective, protection from anoxia and reoxygenation damage, central nervous system, protective effects on cardiac cells, anti-neoplastic, enhancing immunity, protective against ischemic cerebral damages, tonify liver, sedative heart, restrain sweat, generate saliva (16) .
Cardiovascular system/white blood cells/skin conditions effects, anti-cancer, estrogen-like effects (17) .
Lipid-lowering, liver protection, cardiovascular/ diuretic/lipid metabolism effect (18).
Regulatory T cell's separation and purification
Spleens were harvested from mice 6 to 8 weeks old, gently cut into small pieces and passed through cell strainers. Red blood cells were lysed. To purify CD4 
Osteoclast culture and TRAP staining in vitro
Bone marrow-derived monocyte/macrophage precursor cells (BMMs) of 10-week-old mouse femurs were cultured in MEM without phenol red supplemented with FBS in the presence of 10 ng/mL M-CSF for 2 days and then differentiated into osteoclasts using 50 ng/ml RANKL and 10 ng/mL M-CSF for 3 days.
To estimate the effect of Tregs on osteoclastogenesis in vitro, the cells were exposed to BSNXD (10% serum) or estrogen (10 -9 M) or solvent control with or without Tregs in presence of RANKL stimulation for 72 hours.
Then, osteoclastogenesis was calculated by TRAP staining by means of the Leukocyte Acid Phosphatase Kit. TRAP-positive multinucleated cells (TRAP + MNCs; more than five nuclei) were counted under microscope. Results from at least six independent experiments are shown.
Statistical analysis
All values are expressed as the mean ± standard error of the mean (S.E.M.). Data were analyzed by using SPSS and the variance was evaluated by using oneway analyses of variance (ANOVA). p < 0.05 was considered statistically significant.
Results
BSNXD improves the proportion of T cells in the spleen of ovariectomized mice
Activated T cells participate in osteoclast maturation by secreting RANKL. In this study, we assessed the proportion of CD4 + and CD8 + T cell subsets. We found that both CD4 + and CD8 + T cells were increased in the OVX group, but the cells were both decreased in the OVX+BSNXD and OVX+ estrogen groups (p < 0.05, Figure 1 ). 
BSNXD increases CTLA-4 + Tregs in the spleen of ovariectomized mice
BSNXD and BSNXD serum preparation
BSNXD was obtained from the pharmacy of the Hospital of Obstetrics and Gynecology, Fudan University, Shanghai, China. BSNXD was formulated in accordance with traditional Chinese medicine theory and the clinical experience of the authors. BSNXD crude herbs were taken together, and then dissolved in double distilled water. BSNXD solution was intragastric administration to C57BL/6 mice, 7 days later, mice were sacrificed and heart blood was collected. Heart blood was solidification under the normal temperature for a half hour, and blood serum was collected for future use.
Mice
C57BL/6 mice (6-8 weeks) were purchased from the Laboratory Animal Facility of the Chinese Academy of Sciences (Shanghai, China). Housing and handling was in accordance with the guidelines of the Chinese Council for Animal Care. The mice were divided into 4 groups and treated by oral administration: sham group treated with saline (n = 15), OVX (ovariectomized) group treated with saline (n = 15), OVX+BSNXD group treated with BSNXD (total raw herbs 1 g/mL, n = 15), and OVX+ estrogen group treated with 17-β-estradiol (100 μg/kg/day orally, n = 15). After 12 weeks, the spleens and bones were collected for flow cytometry analysis of splenocytes and cells in the bone marrow.
Flow cytometry analysis
Splenocytes and bone marrow cells (1 × 10 6 ) were incubated for 30 minutes on ice with the indicated antibodies, washed, and resuspended in PBS containing 1% bovine serum albumin and 0.1% sodium azide. The non-specific signal was estimated by incubation with rat FITC-and PE-conjugated IgG isotype controls. CD62L (L-selectin) is a cell adhesion molecule expressed on lymphocytes and acts as a "homing receptor". CD62L is also expressed on central memory T cells that have encountered antigen to enable them to localize to secondary lymphoid organs. Compared with the sham group, CD62L was decreased in the OVX group, while it was increased after treatment with BSNXD or estrogen (p < 0.05, Figure 2e , f).
BSNXD decreases the proportion of B cells in the spleen and bone marrow
B cells produce RANKL and OPG, which increases after T-cell stimulation, and they are the major source of OPG in the bone marrow (26) . Compared with the sham group, both CD19 + and B220 + B cells in the spleen were increased in the OVX group, but the cells decreased after BSNXD and estrogen treatments (p < 0.05, Figure 3a , b, e, f). The same phenomenon was found in the lymphocytes of the bone marrow; BSNXD and estrogen treatments lessened the extent of the increase by ovariectomy (p < 0.05, Figure 3c, d ).
BSNXD has no effect on γδ T cells in the spleen and bone marrow
To analyze the influence of γδ T cells on the bone (27), we assessed the percentage of γδ T cells in the spleen. Compared with the sham group, splenic γδ T cells were decreased in the OVX group, but the percentage did not change in the OVX+BSNXD and OVX+ estrogen groups (p > 0.05, Figure 4a , b).
BSNXD increases NK cell numbers in the spleen and bone marrow
Natural killer (NK) cells are bone marrow-derived cells that play a crucial role in the immune defense against viral infections. NK cells trigger osteoclast apoptosis in a dose-dependent manner that results in decreased bone erosion (28) . Compared with the sham group, the percentage of splenic NK cells decreased in the OVX group, but the percentage was increased in the OVX+BSNXD and OVX+ estrogen groups (p < 0.05, Figure 4c , d). Though there was no difference in the numbers of bone marrow lymphocytes in the sham and OVX groups, BSNXD and estrogen treatments increased the proportion of NK cells (p < 0.05, Figure 4e , f).
BSNXD decreases the proportion of mononuclear cells in the spleen and bone marrow
Osteoclasts originate from mononuclear cells and can be induced by M-CSF and RANKL. The proportion of 
CD14
+ cells was increased in the OVX group suggesting that there was an increase in osteoclast production. However, it was decreased in the OVX+BSNXD and OVX+ estrogen groups (p < 0.05, Figure 4g, h) . Similarly, in the bone marrow, the proportion of CD14 + cells was decreased after BSNXD or estrogen treatments (p < 0.05, Figure 4i , j).
Tregs decreases osteoclastogenesis
In order to explore the role of Tregs on osteoclast differentiation, we cultured bone marrow monocytes with or without Tregs, and estrogen was also used as a positive control. Compared with control group, BSNXD serum (10%) and estrogen treatment decreased TRAP + multinucleate cells (MNC), and there were less TRAP + MNC when Tregs were added to cell culture system. (p < 0.05). There was no difference in osteoclastogenesis between BSNXD serum group and estrogen group (p > 0.05, Figure 5 ).
Discussion
Immune cells participate in many physiological activities and their role on the bone has attracted much attention. In this study, we analyzed the changes of the percentage of immune cells in the spleen and bone marrow after BSNXD treatment using estrogen as the positive control. We found that both BSNXD and estrogen treatments affected the proportion of immune cells in vivo.
The activation of CD4 + and CD8 + T cells and osteoporosis
T cells produce a number of mediators that influence osteoclast differentiation. Activated T cells produce factors, including RANKL, that strongly stimulate osteolysis, consistent with the association between inflammation and bone loss. However, T cells (particularly naive T cells) also mediate anti-osteoclastogenic activities. T cells can be divided into two major functional compartments: cytotoxic T cells (CTLs) that express CD8 and T helper cells that express CD4. Based on the importance of T cells on the bone, we assessed the proportion of T cells in the spleen. Lymphocytes express estrogen receptors, and in humans, estrogen loss is reported to cause a decline in T cell subsets. Conversely, ovariectomy increases T cell activation and TNF secretion in mice (29) (30) (31) (32) . In our study, we found that ovariectomy increased the proportion of T cells, and BSNXD treatment can reverse this effect. We found an increase in the proportion of CD8 + T cells in the OVX group, which is consistent with the status prior to surgery. Interestingly, Pietschmann et al. found that CD8 + T cells bearing markers suggestive of cell senescence are significantly increased in elderly patients with osteoporotic fractures (33) . Some investigators focused on the CD4/CD8 T cell ratio, which is significantly higher in osteoporotic patients. The total lymphocyte and T cell counts are unchanged compared with controls, and young normal control subjects have CD4/CD8 ratios that are similar to the elderly nonosteoporotic subjects (34).
Protection of Tregs on bone
Tregs suppress immune responses to maintain immune homeostasis and tolerance towards self-antigens (35) . Tregs reduce joint destruction in an arthritis model by elevating the production of osteoclast-inhibiting cytokines. Tregs directly inhibit osteoclast formation through the transmembrane protein CTLA-4. Further studies on CTLA-4 activity can help explain the direct influence of Tregs on osteoclasts (36) . In the present study, ovariectomy induced a decrease in CTLA-4 + Tregs. However, after BSNXD and estrogen treatments, CTLA-4 + Tregs were increased, suggesting a potential inhibitory role of BSNXD and estrogen on osteoclast maturation. Foxp3 is the transcriptional factor for Tregs and many studies have been conducted on the interaction between Foxp3 + Tregs and the bone (37, 38) . In this study, we found that estrogen increased the numbers of Foxp3 + Tregs. In contrast, BSNXD had no effect on the numbers of Foxp3 + Tregs, suggesting that BSNXD and estrogen act through different pathways.
CD62L retains cells in the lymph nodes and its downregulation facilitates the emigration of effector T cells. In this present study, ovariectomy induced a decrease in CD62L. However, BSNXD treatment increased CD62L, suggesting that T cell activation was inhibited, which is consistent with the data shown in Figure 1 . BSNXD inhibited T cell activation by increasing the proportion of CTLA-4 + Tregs.
The controversial role of B cells on bone
Ovariectomy, which causes significant bone loss, increases B220 + pre-B cell numbers, and estrogen deficiency is associated with an increase in bone marrow B220 + B cells, which is not found in humans (39) . In fact, in human males made hypogonadal and selectively replaced with either estrogen or testosterone, estrogen is associated with an increase in the percentage of bone marrow CD19 + B cells (40) (41) (42) (43) . In our study, we found that ovariectomy induced an increase in CD19 + and B220 + B cells, but BSNXD treatment decreased B cell numbers in the BSNXD+OVX group. Though, the influence of B cells on the bone is controversial, their abundance in the bone marrow suggests they have some influence on the bone mass.
The participation of γδ T cells, NK cells, and monocytes on bone metabolism
The T cell-derived proinflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-17 trigger + regulatory T cells were collected through magnetic cell sorting (MACS) by CD4 negative selection and CD25 positive selection and then added to the bone marrow monocyte monoculture system with or without BSNXD serum/estrogen. 3days later, osteoclastogenesis was calcuated by TRAP staining. Brown: osteoclast. *p < 0.05, Data are representative of at least three experiments. bone erosion by increasing the stimulation of osteoclast formation and activity. Recent studies in animal models of rheumatoid arthritis (RA) have implicated that γδ T cells are the major producers of pathogenic IL-17, and activated γδ T cells inhibit osteoclast differentiation and resorptive activity in vitro (27) . Though we found a decrease in γδ T cells in the OVX group, we did not observe a change after BSNXD and estrogen treatments.
Activated NK cells are present in inflammatory sites associated with enhanced bone erosion. NK cells may participate in inducing apoptosis of osteoclasts that have matured and attached to the bone, which decreases bone resorption (44) (45) (46) . Osteoclast precursors are derived from multipotent precursors of the monocytemacrophage lineage (47, 48) . BSNXD and estrogen treatments increased the proportion of NK cells and monocytes in the OVX group.
The difference between BSNXD and estrogen
In the present study, we compared BSNXD with estrogen, and we found they are similar in most of effects on immune cells, but there are also some differences. The most interesting thing is the difference on the expression of Foxp3, CTLA-4 in Treg cells, of which BSNXD increases CTLA-4 expression, but estrogen increases the Foxp3 expression, suggesting a different modulation on regulatory T cells. In vitro experiment, Tregs decreased osteoclastogenesis, especially in BSNXD serum and estrogen group. In previous research, we also found there are some differences between BSNXD and estrogen on the effect of regulating mesenchymal stem cell differentiation: BSNXD increases MSCs differentiation to osteoblast and decreases MSCs differentiation to adipocyte; while, estrogen increases MSCs differentiation to osteoblast without affecting adipocyte differentiation (49).
Conclusion
In conclusion, the present study showed that BSNXD regulates the proportion of immune cells in the spleen and bone marrow. Regulatory T cells participate in the process of bone protecting. These findings place osteoimmunology in a position of unique clinical significance. BSNXD plays a different role from estrogen on immune cells to regulate the bone metabolism of OVX mice. The link between ovariectomy-induced bone loss and the change in the proportion of immune cells remains to be clarified. 
